Pneumococcal conjugate vaccines for preventing acute otitis media in children

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 5, 2019, Pages

  Fortanier, Alexandre C ^a   Venekamp, Roderick P ^a   Boonacker, Chantal W B ^a   Hak, Eelko ^b   Schilder, Anne G M ^a,c   Sanders, Elisabeth A M ^d,e   Damoiseaux, Roger A M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; CAUSAL ATTRIBUTION; CHILD HEALTH; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; OUTCOME ASSESSMENT; PAIN; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK REDUCTION; SKIN REDNESS; STREPTOCOCCUS PNEUMONIA; SWELLING; SYSTEMATIC REVIEW;

EID: 85028776304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858     Document Type: Review

References (101)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000;19(3):187-95.
2. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatric Infectious Disease Journal 2003;22:10-6.
3. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatric Infectious Disease Journal 2001;20(10):951-8.
4. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001;344(6):403-9.
5. Palmu AA, Saukkoriipi A, Jokinen J, Leinonen M, Kilpi TM. Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media. Vaccine 2009;27:1490-1.
6. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. Journal of Pediatrics 2008;153:764-70.
7. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharidemeningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clinical Infectious Diseases 2003;37(9):1155-64.
8. O’Brien KL, David AB, Chandran A, Moulton LH, Reid R, Weatherholtz R, et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatric Infectious Disease Journal 2008;27:71-3.
9. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomised doubleblind efficacy study. Lancet 2006;367(9512):740-8.
10. Sáez-Llorens X, Rowley S, Wong D, Rodríguez M, Calvo A, Troitiño M, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - a randomized controlled trial. Human Vaccines and Immunotherapeutics 2017;13(6):1-16.
11. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a doubleblind randomized controlled trial. PLOS Medicine 2014;11 (6):e1001657.
12. van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?. International Journal of Pediatric Otorhinolaryngology 2006;70(2):275-85.
13. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003;361(9376):2189-95.
14. Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, et al. Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media - a double-blind randomized clinical trial in Finland. Journal of the Pediatric Infectious Disease Society 2016;5(3):237-48.
15. Gisselsson-Solén M, Melhus A, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - a randomized study. Acta Paediatrica 2011;100:1354-8.
16. Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clinical Infectious Diseases 2012;55:1673-6.
17. Le TM, Rovers MM, Veenhoven RH, Sanders EA, Schilder AG. Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year. European Journal of Pediatrics 2007;166:1049-52.
18. Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infectious Diseases 2014;14(3):205-12.
19. Palmu AA, Kaijalainen T, Jokinen J, Kilpi TM. Efficacy of the 7-valent pneumococcal conjugate vaccine against acute otitis media caused by serotype 6C pneumococcus. Pediatric Infectious Disease Journal 2015;34(7):796-7.
20. Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al. Effectiveness of the ten-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial. Pediatric Infectious Disease Journal 2015;34(11):1230-5.
21. Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine 2018;36(14):1816-22.
22. Roy E, Steinhoff MC, Omer SB, Arifeen SE, Raqib R, Breiman R, et al. Clinical effectiveness of pneumococcal conjugate vaccine in suppurative otitis media: a randomized controlled trial in Bangladeshi infants. Pediatric Academic Societies Annual Meeting. Boston (MA), USA, April 28-May 1 2011.
23. Sarasoja I, Jokinen J, Lahdenkari M, Kilpi T, Palmu AA. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatric Infectious Disease Journal 2013;32(5):517-20.
24. Ahmed S, Shapiro NL, Bhattacharyya N. Incremental health care utilization and costs for acute otitis media in children. Laryngoscope 2014;124(1):301-5.
25. Allemann A, Frey PM, Brugger SD, HiltyM. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland. Vaccine 2017;35(15):1946-53.
26. Alpert HR, Behm I, Connolly GN, Kabir Z. Smoke-free households with children and decreasing rates of paediatric clinical encounters for otitis media in the United States. Tobacco Control 2011;20(3):207-11.
27. Andersen PK, Gill RD. Cox regression model for counting processes: a large sample study. Annals of Statistics 1982;10 (4):1100-20.
28. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADEWorking Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490.
29. Barenkamp SJ, Chonmaitree T, Hakansson AP, Heikkinen T, King S, Nokso-Koivisto J, et al. Panel 4: Report of the Microbiology Panel. Otolaryngology Head and Neck Surgery 2017;156(Suppl 4):S51-62.
30. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clinical Infectious Diseases 2014;59(12):1724-32.
31. Biesbroek G, Wang X, Keijser BJ, Eijkemans RM, Trzciski K, Rots NY, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerging Infectious Diseases Journal 2014;20(2):201-10.
32. Block SL. Searching for the Holy Grail of acute otitis media. Archives of Disease in Childhood 2006;91(12):959-61.
33. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatric Infectious Disease Journal 1992;11(8 Suppl):7-11.
34. Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 2011;29(3):199-211.
35. Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatric Infectious Disease Journal 2013;32: 805-9.
36. Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Review of Vaccines 2017;16 (7):1-14.
37. Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010;304:2161-9.
38. Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatric Infectious Disease Journal 1997;16(11):1053-9.
39. Dagan R, Pelton S, Bakaletz L, Cohen R. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infectious Diseases 2016;16(4):480-92.
40. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatric Infectious Disease Journal 1999;18(6):543-51.
41. Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Deutsches Ärzteblatt International 2016;113(9):139-46.
42. Eythorsson E, Hrafnkelsson B, Erlendsdóttir H, Gudmundsson SA, Kristinsson KG, Haraldsson Á. Decreased acute otitis media with treatment failure after introduction of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine. Pediatric Infectious Disease Journal 2018;37(4):361-6.
43. FadenH, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/ Williamsville Pediatrics. Journal of Infectious Diseases 1997;175(6):1440-5.
44. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clinical Infectious Diseases 2008;46(5):726-31.
45. Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatric Infectious Disease Journal 2017;36(11):1027-31.
46. GRADEpro GDT 2015 [Computer program]
47. McMaster University (developed by Evidence Prime).
48. GRADEpro GDT. Version accessed 16 August 2018.
49. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
50. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. New England Journal of Medicine 1999;340 (4):260-4.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
52. JacobsMR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrobial Agents and Chemotherapy 1998;42(3):589-95.
53. Jahn-Eimermacher A, du Prel JB, Schmitt HJ. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials. Vaccine 2007;25(33):6237-44.
54. Kaur R, Morris M, Pichichero M. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics 2017;140(3):e20170181.
55. Kawai K, Adil EA, Barrett D, Manganella J, Kenna MA. Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination. Journal of Pediatrics 2018;201:122-7.
56. Kvaerner KJ, Nafstad P, Hagen JA, Mair IW, Jaakkola JJ. Recurrent acute otitis media: the significance of age at onset. Acta Oto-Laryngologica 1997;117(4):578-84.
57. Lau WC, Murray M, El-Turki A, Saxena S, Ladhani S, Long P, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine 2015;33(39):5072-9.
58. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance - the need for global solutions. Lancet Infectious Diseases 2013;13(12):1057-98.
59. Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatric Infectious Disease Journal 1994;13(11):983-9.
60. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
61. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. Pediatrics 2013;131(3): e964-99.
62. Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Makela PH. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scandinavian Journal of Infectious Diseases 1981;13(3):177-83.
63. Magnus MC, Vestrheim DF, Nystad W, Håberg SE, Stigum H. Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination. Pediatric Infectious Disease Journal 2012;31(9):951-5.
64. Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatrics 2014;168(1):68-75.
65. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989.
66. Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLOS ONE 2012;7(4):e36226.
67. Moulton LH, O’Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, et al. Design of a group-randomized Streptococcus pneumoniae vaccine trial. Controlled Clinical Trials 2001;22:438-52.
68. NCT01545375 NCT01545375. Evaluation of a vaccine for reducing ear and lung infections in children. clinicaltrials.gov/ct2/show/study/NCT01545375 (first received 6 March 2012).
69. O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of a seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003;362(9381):255-61.
70. O’Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics 2009; 123:1452-63.
71. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348(9022):271-2.
72. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381(9862):214-22.
73. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009;123(6): e1103-10.
74. Pettigrew MM, Alderson MR, Bakaletz LO, Barenkamp SJ, Hakansson AP, Mason KM. Panel 6: Vaccines. Otolaryngology Head and Neck Surgery 2017;156(Suppl 4): 76-87.
75. Pichichero ME, Casey JR, Almudevar A. Nonprotective responses to pediatric vaccines occur in children who are otitis prone. Pediatric Infectious Disease Journal 2013;32 (11):1163-8.
76. Poehling KA, Szilagyi PG, Grijalva CG,Martin SW, LaFleur B, Mitchel E, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007;119(4):707-15. Review Manager 2014 [Computer program]
77. Nordic Cochrane Centre, The Cochrane Collaboration.
78. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2015.
79. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006;368(9545):1429-35.
80. Schilder AG, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML, Haggard MP, et al. Otitis media. Nature Reviews Disease Primer 2016;2:16063.
81. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatric Infectious Disease Journal 1999;18(9):757-63.
82. Sigurðsson S, Eythorsson E, Hrafnkelsson B, Erlendsdóttir H, Kristinsson KG, Haraldsson Á. Reduction in all-cause acute otitis media in children less than three years of age in primary care following pneumococcal vaccination with PHiD-CV10: a whole population study. Clinical Infectious Diseases 2018 March 30 Epub ahead of print]. DOI: 10.1093/cid/ciy233
83. Somech I, Dagan R, Givon-Lavi N, Porat N, Raiz S, Leiberman A, et al. Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine 2011;29: 4202-9.
84. Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends in otitis media treatment failure and relapse. Pediatrics 2008;121:674-9.
85. Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLOS ONE 2012;7(6):e39730.
86. Tamir SO, Roth Y, Dalal I, Goldfarb A, Grotto I, Marom T. Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era. Pediatric Infectious Disease Journal 2015;34(2):195-9.
87. Tamir SO, Shemesh S, Oron Y, Marom T. Acute otitis media guidelines in selected developed and developing countries: uniformity and diversity. Archives of Disease in Childhood 2017;102(5):450-7.
88. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clinical Infectious Diseases 2012;54(12):1765-73.
89. van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clinical Infectious Diseases 2013;56(3):e30-9.
90. van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLOS ONE 2011;6(6):e20229.
91. Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clinical Infectious Diseases 2004;39(7):911-9.
92. Venekamp RP, Sanders SL, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database of Systematic Reviews 2015, Issue 6. DOI: 10.1002/14651858.CD000219.pub4
93. World Health Organization. Pneumococcal vaccines WHO position paper - 2012 - Recommendations. Vaccine 2012;30(32):4717-8.
94. Wiertsema SP, Kirkham LA, Corscadden KJ, Mowe EN, Bowman JM, Jacoby P, et al. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Vaccine 2011;29(32):5163-70.
95. Wiertsema SP, Corscadden KJ, Mowe EN, Zhang G, Vijayasekaran S, Coates HL, et al. IgG responses to pneumococcal and Haemophilus influenzae protein antigens are not impaired in children with a history of recurrent acute otitis media. PLOS ONE 2012;7(11): e49061.
96. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008;121:253-60.
97. Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2014, Issue 4. DOI: 10.1002/14651858.CD001480.pub4
98. Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2009, Issue 2. DOI: 10.1002/14651858.CD001480.pub3
99. Straetemans M, Sanders EA, Veenhoven RH, Schilder AG, Damoiseaux RA, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2002, Issue 2. Art, No.: CD001480. DOI: 10.1002/14651858.CD001480
100. Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatric Infectious Disease Journal 2003;22(6):515-24.
101. Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database of Systematic Reviews 2004, Issue 1. DOI: 10.1002/14651858.CD001480.pub2